MRANK-106

N/A

Report date: 2025/04/16 18:08:12
NMEFirst In Class

Base Information

Drug NameMRANK-106
Drug Alias NameMRANK-106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitorsYes tyrosine protein kinase inhibitors
TargetsSerine/threonine-protein kinase WEE1Yes tyrosine protein kinase
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsSmall Cell Lung Carcinoma +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMindRank Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMindRank Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsSmall Cell Lung Carcinoma +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A